Bridgebio Pharma Stock Probability of Future Stock Price Finishing Over 26.83
| BBIO Stock | USD 23.42 0.18 0.77% |
BridgeBio |
BridgeBio Pharma Target Price Odds to finish over 26.83
The tendency of BridgeBio Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 26.83 or more in 90 days |
| 23.42 | 90 days | 26.83 | about 25.98 |
Based on a normal probability distribution, the odds of BridgeBio Pharma to move over $ 26.83 or more in 90 days from now is about 25.98 (This BridgeBio Pharma probability density function shows the probability of BridgeBio Stock to fall within a particular range of prices over 90 days) . Probability of BridgeBio Pharma price to stay between its current price of $ 23.42 and $ 26.83 at the end of the 90-day period is about 61.33 .
Given the investment horizon of 90 days BridgeBio Pharma has a beta of 0.94 suggesting BridgeBio Pharma market returns are highly reactive to returns on the market. As the market goes up or down, BridgeBio Pharma is expected to follow. Additionally BridgeBio Pharma has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. BridgeBio Pharma Price Density |
| Price |
Predictive Modules for BridgeBio Pharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as BridgeBio Pharma. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.BridgeBio Pharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. BridgeBio Pharma is not an exception. The market had few large corrections towards the BridgeBio Pharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold BridgeBio Pharma, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of BridgeBio Pharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.16 | |
β | Beta against Dow Jones | 0.94 | |
σ | Overall volatility | 1.91 | |
Ir | Information ratio | -0.05 |
BridgeBio Pharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of BridgeBio Pharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for BridgeBio Pharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| BridgeBio Pharma generated a negative expected return over the last 90 days | |
| BridgeBio Pharma has high historical volatility and very poor performance | |
| BridgeBio Pharma has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 9.3 M. Net Loss for the year was (653.25 M) with profit before overhead, payroll, taxes, and interest of 74.21 M. | |
| BridgeBio Pharma currently holds about 715.71 M in cash with (527.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.83. | |
| BridgeBio Pharma has a poor financial position based on the latest SEC disclosures | |
| Over 94.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from investing.com: BridgeBio Pharma CFO Brian Stephenson sells shares worth 93,136 |
BridgeBio Pharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of BridgeBio Stock often depends not only on the future outlook of the current and potential BridgeBio Pharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. BridgeBio Pharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 162.8 M | |
| Cash And Short Term Investments | 434.9 M |
BridgeBio Pharma Technical Analysis
BridgeBio Pharma's future price can be derived by breaking down and analyzing its technical indicators over time. BridgeBio Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of BridgeBio Pharma. In general, you should focus on analyzing BridgeBio Stock price patterns and their correlations with different microeconomic environments and drivers.
BridgeBio Pharma Predictive Forecast Models
BridgeBio Pharma's time-series forecasting models is one of many BridgeBio Pharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary BridgeBio Pharma's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about BridgeBio Pharma
Checking the ongoing alerts about BridgeBio Pharma for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for BridgeBio Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| BridgeBio Pharma generated a negative expected return over the last 90 days | |
| BridgeBio Pharma has high historical volatility and very poor performance | |
| BridgeBio Pharma has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 9.3 M. Net Loss for the year was (653.25 M) with profit before overhead, payroll, taxes, and interest of 74.21 M. | |
| BridgeBio Pharma currently holds about 715.71 M in cash with (527.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.83. | |
| BridgeBio Pharma has a poor financial position based on the latest SEC disclosures | |
| Over 94.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from investing.com: BridgeBio Pharma CFO Brian Stephenson sells shares worth 93,136 |
Check out BridgeBio Pharma Backtesting, BridgeBio Pharma Valuation, BridgeBio Pharma Correlation, BridgeBio Pharma Hype Analysis, BridgeBio Pharma Volatility, BridgeBio Pharma History as well as BridgeBio Pharma Performance. To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BridgeBio Pharma. If investors know BridgeBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BridgeBio Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.42) | Revenue Per Share 1.194 | Quarterly Revenue Growth (0.33) | Return On Assets (0.49) | Return On Equity (17.90) |
The market value of BridgeBio Pharma is measured differently than its book value, which is the value of BridgeBio that is recorded on the company's balance sheet. Investors also form their own opinion of BridgeBio Pharma's value that differs from its market value or its book value, called intrinsic value, which is BridgeBio Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BridgeBio Pharma's market value can be influenced by many factors that don't directly affect BridgeBio Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BridgeBio Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if BridgeBio Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BridgeBio Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.